The Relationship of Attention Deficit/Hyperactivity Disorder and the Self-Esteem of College Women

The symptoms of females with Attention Deficit/Hyperactivity Disorder (AD/HD) have been underreported, possibly due to the fact that their symptoms of inattention are often overlooked. Research has revealed that individuals report low selfesteem as a result of undiagnosed AD/HD. Thus, if these individuals are not diagnosed and exposed to the proper treatment for their AD/HD symptoms, they may continue to endure progressive psychological impairments in the years to come. The current study is an attempt to contribute to the literature concerning the presentation and outcome of AD/HD in women. This study aims to determine the relationship of self esteem and AD/HD in college women. A sample of 74 women participated in this study. A total of 24 students diagnosed with AD/HD and 50 students without AD/HD comprised the sample. Participants completed a demographic questionnaire and an AD/HD and Self-Esteem inventory. Results of this study indicated that women who were diagnosed with AD/HD scored higher than the comparison sample on all scales measuring AD/HD symptoms. As predicted, AD/HD symptoms were found to be negatively related to self-esteem. On the other hand, no significant correlations were found between the age of women when they were first diagnosed with AD/HD and their current level of self-esteem. It was also determined that family support was related self-esteem. Thus, family support was examined as a moderator of the relation between self-esteem and AD/HD. Unfortunately, family support does not appear to moderate the relation between AD/HD and self-esteem. Limitations of this study included a small sample size, the use of self-reports, not examining subtypes of AD/HD individually, and not requiring a medication abstinence period. Despite limitations, this study provides some insight on the outcomes of women with AD/HD. It also provides evidence for the need of additional research in the area of women with AD/HD; their life-span experience with AD/HD and the effects of a late diagnosis. Further studies in this area of interest that include larger sample sizes from multiple postsecondary institutions will be necessary to determine that the results in this study are in fact generalizable to other college women diagnosed with AD/HD

Toward high-throughput synthesis of complex natural product-like compounds in the genomics and proteomics age

In the age of high-throughput biology, novel genes and proteins are emerging quickly. the need for developing organic synthesis-derived methods that allow rapid access to polyfunctional, complex natural product-like compounds is growing constantly, largely because these small-molecule-based compounds serve as smart, powerful tools both in understanding the roles and functions of emerging biological targets and in validating their biological responses. Developing asymmetric synthesis-derived organic reactions on solid phase allows the sythesis of complex natural product-like compounds in a high-throughput manner. Solid phase organic sythesis is now commonly utilized in the library synthesis of rather simple compounds (i.e., compounds with no multiple stereogenic centers). With few exceptions, the sythesis of complex natural product-like derivatives is still in its infancy. Some recent efforts made in this area indicate opportunities yet to be explored.NRC publication: Ye

Best Practices to Diversify Chemistry Faculty

Many academic institutions have looked at various ways to make their faculty a more diverse and inclusive group of people that better reflect the demographic swath of their current and future student bodies. This is even more so important in chemistry departments, where there has long been a discussion on the “leaky pipeline” for women and underrepresented groups. The work presented here examines programs and policies at various departments aimed at increasing the diversity of their faculty applicant pool, and compares them against the reception of the general scientific community by way of applicant demographics and the use of a survey instrument designed to ascertain the advertisement language that lends to a more diverse applicant pool. The combination of these results is then used to generate a list of best practices that administrations and academic search committees can use to improve their ability to attract diverse talent

Regulatory T cells targeting a pathogenic MHC class II: Insulin peptide epitope postpone spontaneous autoimmune diabetes

IntroductionIn spontaneous type 1 diabetes (T1D) non-obese diabetic (NOD) mice, the insulin B chain peptide 9-23 (B:9-23) can bind to the MHC class II molecule (IAg7) in register 3 (R3), creating a bimolecular IAg7/InsulinB:9-23 register 3 conformational epitope (InsB:R3). Previously, we showed that the InsB:R3-specific chimeric antigen receptor (CAR), constructed using an InsB:R3-monoclonal antibody, could guide CAR-expressing CD8 T cells to migrate to the islets and pancreatic lymph nodes. Regulatory T cells (Tregs) specific for an islet antigen can broadly suppress various pathogenic immune cells in the islets and effectively halt the progression of islet destruction. Therefore, we hypothesized that InsB:R3 specific Tregs would suppress autoimmune reactivity in islets and efficiently protect against T1D.MethodsTo test our hypothesis, we produced InsB:R3-Tregs and tested their disease-protective effects in spontaneous T1D NOD.CD28-/- mice.ResultsInsB:R3-CAR expressing Tregs secrete IL-10 dominated cytokines upon engagement with InsB:R3 antigens. A single infusion of InsB:R3 Tregs delayed the onset of T1D in 95% of treated mice, with 35% maintaining euglycemia for two healthy lifespans, readily home to the relevant target whereas control Tregs did not. Our data demonstrate that Tregs specific for MHC class II: Insulin peptide epitope (MHCII/Insulin) protect mice against T1D more efficiently than polyclonal Tregs lacking islet antigen specificity, suggesting that the MHC II/insulin-specific Treg approach is a promising immune therapy for safely preventing T1D

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.

BACKGROUND: Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection. METHODS: In this multicentre, randomised, double-blind, placebo-controlled trial, adults (≥18 years) with S aureus bacteraemia who had received ≤96 h of active antibiotic therapy were recruited from 29 UK hospitals. Patients were randomly assigned (1:1) via a computer-generated sequential randomisation list to receive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus identical placebo, together with standard antibiotic therapy. Randomisation was stratified by centre. Patients, investigators, and those caring for the patients were masked to group allocation. The primary outcome was time to bacteriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisation to 12 weeks, adjudicated by an independent review committee masked to the treatment. Analysis was intention to treat. This trial was registered, number ISRCTN37666216, and is closed to new participants. FINDINGS: Between Dec 10, 2012, and Oct 25, 2016, 758 eligible participants were randomly assigned: 370 to rifampicin and 388 to placebo. 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) had nosocomial S aureus infections. 47 (6%) had meticillin-resistant infections. 301 (40%) participants had an initial deep infection focus. Standard antibiotics were given for 29 (IQR 18-45) days; 619 (82%) participants received flucloxacillin. By week 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1·4%, 95% CI -7·0 to 4·3; hazard ratio 0·96, 0·68-1·35, p=0·81). From randomisation to 12 weeks, no evidence of differences in serious (p=0·17) or grade 3-4 (p=0·36) adverse events were observed; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group had antibiotic or trial drug-modifying adverse events (p=0·004), and 24 (6%) versus six (2%) had drug interactions (p=0·0005). INTERPRETATION: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia. FUNDING: UK National Institute for Health Research Health Technology Assessment

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

The Relationship of Attention Deficit/Hyperactivity Disorder and the Self-Esteem of College Women

The symptoms of females with Attention Deficit/Hyperactivity Disorder (AD/HD) have been underreported, possibly due to the fact that their symptoms of inattention are often overlooked. Research has revealed that individuals report low selfesteem as a result of undiagnosed AD/HD. Thus, if these individuals are not diagnosed and exposed to the proper treatment for their AD/HD symptoms, they may continue to endure progressive psychological impairments in the years to come. The current study is an attempt to contribute to the literature concerning the presentation and outcome of AD/HD in women. This study aims to determine the relationship of self esteem and AD/HD in college women. A sample of 74 women participated in this study. A total of 24 students diagnosed with AD/HD and 50 students without AD/HD comprised the sample. Participants completed a demographic questionnaire and an AD/HD and Self-Esteem inventory. Results of this study indicated that women who were diagnosed with AD/HD scored higher than the comparison sample on all scales measuring AD/HD symptoms. As predicted, AD/HD symptoms were found to be negatively related to self-esteem. On the other hand, no significant correlations were found between the age of women when they were first diagnosed with AD/HD and their current level of self-esteem. It was also determined that family support was related self-esteem. Thus, family support was examined as a moderator of the relation between self-esteem and AD/HD. Unfortunately, family support does not appear to moderate the relation between AD/HD and self-esteem. Limitations of this study included a small sample size, the use of self-reports, not examining subtypes of AD/HD individually, and not requiring a medication abstinence period. Despite limitations, this study provides some insight on the outcomes of women with AD/HD. It also provides evidence for the need of additional research in the area of women with AD/HD; their life-span experience with AD/HD and the effects of a late diagnosis. Further studies in this area of interest that include larger sample sizes from multiple postsecondary institutions will be necessary to determine that the results in this study are in fact generalizable to other college women diagnosed with AD/HD

Combinatorial chemistry in the age of chemical genomics

Peer reviewed: YesNRC publication: N

Exploring new chemical space by stereocontrolled diversity-oriented synthesis

Natural products that act as highly specific, small-molecule protein-binding agents and as modulators of protein-protein interactions are highly complex and exhibit functional groups with three-dimensional and stereochemical diversity. The complex three-dimensional display of chiral functional groups appears to be crucial for exhibiting specificity in protein binding and in differentiating between closely related proteins. The development of methods that allow a high-throughput access to three-dimensional, skelatally complex, polycyclic compounds having few asymmetric diversity sites is essential and a highly challenging task. In the postgenomic chemical biology age, in which there is a great desire to understand protein-protein interactions and to dissect protein networking-based signaling pathways by small molecules, the need for developing "stereocontrolled, diversity-oriented synthesis" methods to generate natural product like libraries is of utmost importance.NRC publication: Ye